Modotuximab
Appearance
Monoclonal antibody | |
---|---|
Type | Whole antibody |
Source | Chimeric |
Target | HER1 |
Clinical data | |
ATC code |
|
Identifiers | |
CAS Number | |
ChemSpider |
|
UNII | |
KEGG |
Modotuximab (INN; formerly zatuximab[1]) is a chimeric monoclonal antibody designed for the treatment of cancer.[2] It acts as an immunomodulator and binds to HER1.[3]
References
[edit]- ^ Wilkinson I, Hale G (2022). "Systematic analysis of the varied designs of 819 therapeutic antibodies and Fc fusion proteins assigned international nonproprietary names". mAbs. 14 (1): 2123299. doi:10.1080/19420862.2022.2123299. PMC 9481088. PMID 36109838.
- ^ Alifrangis L, Schoemaker R, Skartved NJ, Hald R, Montagut C, Kopetz S, et al. (February 2020). "Population pharmacokinetics and covariate analysis of Sym004, an antibody mixture against the epidermal growth factor receptor, in subjects with metastatic colorectal cancer and other solid tumors". Journal of Pharmacokinetics and Pharmacodynamics. 47 (1): 5–18. doi:10.1007/s10928-019-09663-2. PMID 31679083.
- ^ World Health Organization (2012). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 107" (PDF). WHO Drug Information. 26 (2).